Abstract
Publisher Summary The mushrooming of the field of cellular transplantation in recent years has given rise to a new way of supplying analgesic molecules. In animal models, cell-transplant analgesia has proven successful both with cells from primary tissue (mostly in studies with adrenal medullary chromaffin cells) and with immortalized, bioengineered cell lines that secrete pain-reducing neuroactive substances. The choice of donor material for cell-transplant analgesia presents some interesting contrasts with other neural transplant therapies. Homotypic tissue is a realistic choice as replacement material for repair of deficits, such as those seen in Parkinson's disease or spinal trauma. However, heterotypic tissue shows an apparently coincidental but useful concordance with the function of the local host tissue. This is most remarkable in the case of the adrenal medulla for spinal analgesia. Preclinical pain models of several types have by now confirmed that adrenal medullaty chromaffin cells can be analgesic when transplanted into the rat's spinal subarachnoid space.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
